Patent · US Active

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

US9789182B2 · kind B2 · utility

5Cited by

0References

15Claims

0Family size

Assignees

Bristol-Myers Squibb Company · US
INNATE PHARMA · FR

Inventors

Robert Graziano · Princeton, US
Ashok K. Gupta · Clarksburg, US
Su Young Kim · Gwangyang-si, KR
Jon M. Wigginton · Rockville, US
Pascale Andre · Marseilles, FR

Key dates

Filing date	Oct 23, 2013
Grant date	Oct 17, 2017
Priority date	—
Expiry date	Nov 24, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.